# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused o...
Needham analyst David Saxon reiterates Sight Sciences (NASDAQ:SGHT) with a Hold.
Clinical results demonstrate long-term efficacy of the OMNI® Surgical System for primary open-angle glaucoma and support use of...
Stifel analyst Thomas Stephan maintains Sight Sciences (NASDAQ:SGHT) with a Buy and raises the price target from $6 to $7.